2026
9. - 10. April

SNOG Northern Lights Neuroscience Symposium COPENHAGEN

Programme

Last updated: January 29, 2026

April 8 - 10, 2026

Welcome to the SNOG – Northern Lights Neuroscience Symposium in Copenhagen spring 2026.

This symposium is organized as a collaboration between the Scandinavian Neuro-oncology (SNOG) symposia – the leading meeting in the field of neuro-oncology in the Nordic region and the NORTHERN LIGHTS NEUROSCIENCE SYMPOSIA – the leading Nordic meeting in the field of neuropathology.

Our symposium will be a multiprofessional interdisciplinary symposium that will make it possible to share cutting-edge results and foster collaborations that will bring our field forward in the fight against brain cancer.

We look forward to insightful discussions and inspiring connections in beautiful Copenhagen this spring.

Warm regards,
On behalf of the Organising Committee
Bjarne Winther Kristensen

Overall programme – tentative

Wednesday, April 8, 2026
Wellcome reception, Copenhagen City Hall

Thursday, April 9, 2026
Session 1: Molecular brain tumor classification and concepts in tumor biology
Session 2: Microenvironment
Session 3: AI and novel therapeutic approaches
Session 4: Meningiomas
Session 5: Neurosurgery
Conference dinner and boat trip, Langelinje Pavilion, Copenhagen habour (Special registration required)

Friday, April 10, 2026
Session 6: Clinical trials - and radiation therapy
Session 7: Symptom management and quality of life
Session 8: Neuroimaging and theranostics
Session 9: Immunotherapy and trial updates

Wednesday, April 8, 2026

19:30
Welcome Reception
Copenhagen City Hall
Come and meet your fellow participants at the Welcome Reception at the beautiful Copenhagen City Hall and enjoy the famous City Hall pancakes. Participation is included in the registration fee.

A heartfelt tahnk you to

Kræftens Bekæmpelse
the Danish Cancer Society

LUNDBECK FOUNDATION

Thursday, April 9, 2026

8:30
Welcome

8:40
Session 1
Molecular brain tumor classification and concepts in tumor biology

Felix Sahm - Heidelberg, Germany
Next level diagnostics

Olivera Casar-Borota - Uppsala, Sweden
Towards a molecular classification of PitNETs

Mario Suva - Boston, USA
Single-cell and spatial transcriptomic analysis of human gliomas

David Scheie - Copenhagen, Denmark
How nanopore sequencing has revolutionized CNS tumors diagnostics

Presentation based on selected abstract

10:20
Coffee / Exhibition / Posters

10:35
Session 2
Microenvironment

Leila Akkari - Amsterdam, The Netherlands
Unveiling macrophage diversity in the brain cancer ecosystem: A matter of plasticity and metabolism

Presentation based on selected abstract

Marco Prinz - Freiburg, Germany
The myeloid side of the brain

11:45
Lunch symposium
Servier

12:45
Session 3
AI and novel therapeutic approaches

Dieter Henrik Heiland - Freiburg, Germany
Molecular guided neurosurgery – from exploration to application

Austin Evans - Tampere, Finland
Multifunctional heparin nanoparticles for therapeutic reprogramming of glioblastoma and beyond

---

Thursday, April 9, 2026 continued

Session 3 - *Continued*
AI and novel therapeutic approaches

Maria Ormhøj - Odense, Denmark
New CAR T-cell approaches to overcome tumor antigen heterogeneity in brain tumors

Presentation based on selected abstract

13:50
Session 4
Meningiomas

Tiit Illimar Mathiesen - Copenhagen, Denmark
Three pitfalls in meningioma management

Anders Korshøj - Aarhus, Denmark
Nationwide population-based trends in incidence, care, and imaging surveillance of meningioma: Results from 8,134 Danish patients (2010-2023)

Mikkel Schou Andersen - Odense, Denmark
Modelling the meningioma - insights from in vivo and in vitro approaches

Presentation based on selected abstract

14:45
Coffee / Exhibition / Posters
Poster session

15:45
Session 5
Neurosurgery

Philipp Karschnia - München, Germany
RESECTography: Mapping the oncological benefit of surgery for personalized glioma resections

Asgeir Jakola - Gothenburg, Sweden
Supramaximal resection in glioblastoma: Current state of the evidence

Jane Skjøth-Rasmussen – Copenhagen, Denmark
Tumor delineation - an update on fluorescent guided surgery in low grade glioma and meningioma using FG001- a uPAR-targeting fluorescent agent

Presentation based on selected abstract

18:00 Congress dinner (Special registration required)
Come and join your fellow participants for the Conference Dinner. We will cruise through Copenhagen Harbour before arriving at the beautiful Langelinie Pavilion on Langelinie Pier, where a delicious three-course menu awaits.

Programme

2026
9. - 10. April

SNOG Northern Lights Neuroscience Symposium

COPENHAGEN

Friday, April 10, 2026

8:30 Session 6
Clinical trials - and radiation therapy

Howard Colman – Utah, USA
Eflornithine plus lomustine improves overall survival and progression-free survival compared to lomustine alone in recurrent astrocytoma, IDH-mutant, WHO grade 3: Updated results of the Phase 3 STELLAR trial

Anna Berghoff – Vienna, Austria
Functional precision medicine: patient derived cell based drug screening in glioblastoma

Kirsi Rautajoki - Tampere, Finland
Progression of IDH-mutant astrocytoma's after therapy

Presentation based on selected abstract

Vincent Fougner - Copenhagen, Denmark
GBM trial design: Lessons learned and new strategies

Petter Brandal – Oslo, Norway
Proton therapy in brain tumors - will we ever know if the promise is fulfilled?

10:20
Coffee / Exhibition / Posters

10:40
Session 7
Symptom management and quality of life

Florien Boele - Leeds, United Kingdom
Quality of life and neurocognitive functioning in brain tumor survivorship

Karin Piil - Copenhagen, Denmark
Understanding the patient needs to build personalized pathways

Anneli Ozanne - Gothenburg, Sweden
Supportive strategies for patients and families along the brain tumor care pathway

Presentation based on selected abstract

11:50
Lunch / Exhibition / Posters
Poster session

12:50
Session 8
Neuroimaging and theranostics

Atle Bjørnerud - Oslo, Norway
Applications of artificial intelligence in neuro-oncology imaging

Friday, April 10, 2026 continued

Session 8 - *Continued*
Neuroimaging and theranostics

Live Eikenes - Trondheim, Norway
68Ga/177Lu-PSMA theranostic in recurrent high-grade glioma

David Bouget – Trondheim, Norway
From pixels to protocols: advancing neurosurgical decision support with AI-based segmentation and reporting

Presentation based on selected abstract

13:50
Coffee / Exhibition / Posters

14:10
Session 9: Immunotherapy and trial updates

Michael Platten – Heidelberg, Germany
Targeting T cells to clonal driver mutations in glioma

Christel Herold-Mende - Heidelberg, Germany
TBA

Anders Korshøj – Aarhus, Denmark
Window-of-opportunity trials in newly diagnosed GBM - challenges and perspectives

Presentation based on selected abstract

15:35 Goodbye and thank you

2026
9. - 10. April

SNOG Northern Lights Neuroscience Symposium

Programme

COPENHAGEN

A heartfelt thank you to the exhibitors & sponsors that support the conference

SERVIER
moved by you

Servier, a global pharmaceutical group

Our vocation: We are committed to therapeutic progress to serve patient needs.

Founded to serve health, Servier is a global group governed by a non-profit Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,900 employees of the Group are committed to this shared vocation, source of inspiration every day.

As a leader in cardiology, Servier's ambition is to become a focused and innovative player in oncology by targeting hard-to-treat cancers. That is why the Group allocates over 70% of its R&D budget to developing targeted and innovative therapies in oncology.

Neuroscience and immuno-inflammatory diseases are the area of focus as this is where we believe we can have the biggest impact. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.

In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine.

In Research & Innovation, our aim is clear—to accelerate the pace of research and efforts to develop new therapeutic solutions guided by a long-term vision.

Servier's independence from market forces means we can invest heavily in R&D to innovate and develop new medicines. That is why we invest over 20% of our sales revenue (excl. generic medicines) each year in R&D.

Headquartered in France, Servier relies on a strong geographical footprint in close to 140 countries and achieved a revenue of €6.9 billion for the financial year ending September 2025.

MARGINUM

Marginum is a Finnish medical device manufacturer and market forerunner in intra-operative aspirate tissue monitoring systems.

Our technology analyses the fluorescence of resected surgical tissue flowing through the suction tube and detects fluorescence indicating malignant tissue. When fluorescence is detected, the surgeon is notified with near-real-time, objective, and precise feedback.

Marginum's products support intra-operative decision-making by providing increased detection of fluorescence directly from aspirated tissue. They integrate seamlessly with existing surgical workflows and are compatible with the most common ultrasonic aspirator systems.

HIVEN® Aspirate Tissue Detector, an MDR CE-marked Class IIb medical device, provides detection of 5-ALA-based fluorescence from aspirated tissue in high-grade glioma surgeries. HIVEN® is **now available in European markets through our distributors.**

Learn more at www.marginum.com.

CARTHERA
Advanced Brain Therapy